Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zuberitamab in Primary Persistent or Chronic ITP (Phase II, China)
CTR20211966Phase 2Terminated
- Sponsor
- Bio-Ray Biotech
- Start
- Aug 2021
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of hlx01 in immune thrombocytopenia (ITP), sponsored by Bio-Ray Biotech. Started Aug 2021; status: terminated.
02
Drugs
hlx01
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on CTR20211966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211966.